NS) CLOSED in this appl ropriate communication v application is subject to	lication. If not included will be mailed in due course. THIS	
cover sheet with the con NS) CLOSED in this appl ropriate communication of application is subject to	rrespondence address lication. If not included will be mailed in due course. THIS	
cover sheet with the con NS) CLOSED in this appl ropriate communication of application is subject to	rrespondence address lication. If not included will be mailed in due course. THIS	
NS) CLOSED in this appl ropriate communication v application is subject to	lication. If not included will be mailed in due course. THIS	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. 1. This communication is responsive to the amendment filed 4/1/05.		
2. The allowed claim(s) is/are 1,4-11,14-18,24-30 and 41-46.		
3. The drawings filed on 22 February 2002 are accepted by the Examiner.		
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
Drawing Review (PTO-9 t / Comment or in the Of	ffice action of gs in the front (not the back) of	
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Interview Summary (I Paper No./Mail Date	e <u>6/16/05</u> .	
	why the oath or declaration ed. Drawing Review (PTO-9 t / Comment or in the Off be written on the drawing cording to 37 CFR 1.121(d) DGICAL MATERIAL meterory EPOSIT OF BIOLOGICA Notice of Informal Pa	

Application/Control Number: 10/081,961

Art Unit: 1636

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Linda R. Judge on 6/16/05.

The application has been amended as follows:

In the **Specification**:

On Page 2, in the Brief Description of Figure 1, insert --(SEQ ID NO:1)-- after "poly(A) site"

On Page 2, in the Brief Description of Figure 2, insert --(SEQ ID NO:2)-- after "control region".

In the Claims:

In Claim 4, delete the word "viral" and substitute --adenoviral--.

In Claim 5, delete the word "viral" and substitute --adenoviral--.

In Claim 6, delete the word "viral" and substitute --adenoviral--.

Application/Control Number: 10/081,961

Art Unit: 1636

In Claim 7, delete the word "viral" and substitute --adenoviral--.

In Claim 8, delete the word "viral" and substitute --adenoviral--.

In Claim 9, delete the word "viral" and substitute --adenoviral--.

In Claim 10, delete the word "viral" and substitute --adenoviral--.

In Claim 11, line 1, after "The", insert --adenoviral--. In line 3, after "said" insert --adenoviral--.

In Claim 18, after the phrase "vector of Claim", delete "17" and substitute --16--.

Cancel Claims 31-40.

In Claim 42, after the phrase "vector of Claim", delete "8" and substitute --41--.

In Claim 44, after the phrase vector of Claim", delete "28" and substitute --43--.

This application is in condition for allowance except for the presence of claims 31-40 directed to an invention non-elected without traverse by applicants on 10/15/04. Accordingly, claims 31-40 have been cancelled.

Art Unit: 1636

Applicants' amendment to the instant claims renders said claims no longer rejectable under obviousness type double patenting over the claims in the co-pending application 10/081,969. The obviousness type double patenting rejection over 10/081,969 is therefore withdrawn.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Guzo, Ph.D., whose telephone number is (571) 272-0767. The examiner can normally be reached on Monday-Thursday from 8:00 AM to 5:30 PM. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel, Ph.D., can be reached on (571) 272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

David Guzo June 22, 2005

PRIMARY EXAMINER